We are developing artificial intelligence models (patent-pending) that can screen and predict outcomes for COVID-19 within the first hour of presentation to emergency departments.
A former faculty member at the National Institutes of Health with over 20 peer-reviewed publications, Artur has built the flight controller software for the world's largest electric "flying car", helped Twitter scale its revenues from under $100M to over $2B, and presently leads the vision and AI at Biocogniv.
Prior to Biocogniv, Tanya was the COO/CTO at the cancer diagnostics company Genomic Expression. She has a PhD in Physical Chemistry from McGill and co-founded a life science instrumentation company (BioTrove) to commercialize the post-doctoral research she did at MIT.
Dr. Levine has been a clinical professor at Yale School of Medicine for over 40 years, and has authored and licensed over 100 patents in medical diagnostics, including several hematology devices like the Quantitative Buffer Coat, which has been commercialized to over $1B in sales.
A Yale, Harvard, and Mass General alum, Harry is the Director of Cardiovascular Services at UVM Medical Center (a $2B/year hospital) and an editor at leading cardiology journals like JACC and Circulation.
As former COO of T2 Biosystems (IPO) and Boston Microfluidics, Sarah has spearheaded the approval of several diagnostic devices with the FDA, and provides valuable guidance to Biocogniv's regulatory strategy.
John is a serial healthcare entrepreneur, having sold an FDA-compliant clinical trial software company to Phase Forward and then Oracle, and led product commercialization teams at various medical companies (JnJ, Abbott, Roche, Oracle, and IBM).
As the founder and CEO of Microstrain Inc., Steve built a technology startup from zero to over 70 employees through its successful exit to LORD Corporation, and now advises and invests in various companies in Vermont.
Dr. Weinberg is an Assistant Professor of Medicine at Cedars-Sinai, triple boarded in pulmonary, critical care, and internal medicine. He has a Master's degree from Cambridge University, and has co-authored several studies and clinical trials in critical care and pulmonary vascular medicine.
Dr. Tapson is a Professor of Medicine and Associate Director in the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center. He has authored over 250 papers and has edited numerous books and chapters in pulmonology and critical care.